Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

NovoCure Surpasses Q1 Expectations

TheMotleyFool

0 0

NovoCure (NASDAQ:NVCR), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street’s estimate of $146 million.

GAAP earnings per share (EPS) were a negative $0.31, beating expectations of a negative $0.46 per share. The quarter was marked by robust patient growth and progress in clinical trials, though challenges in gross margins remain.

Source: Analyst estimates for the quarter provided by FactSet.

Source Fool.com